30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: SpineGuard

(1H13 revenue only)

€2.3MM (~US $3MM), +27% (U.S. ~$2.3MM, +30%)

  • >3,000 PediGuard procedures performed this year
  • U.S. sales =49% of units sold
  • >100 U.S. surgeons using PediGuard regularly
  • Received regulatory clearance to market entire PediGuard range in Russia, Cannulated PediGuard in Mexico